Humacyte Inc (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced on Thursday that it has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common stock pursuant to a registered direct offering.

This offering was led by a new life science dedicated investor and a long-only mutual fund. All of the shares of common stock are being sold by Humacyte and gross proceeds are expected to be USD20m, before deducting offering expenses.

Humacyte intends to use the net proceeds from the offering to fund the commercialisation of Symvess in the vascular trauma indication, the planned filing of a Biologics License Application supplement in a haemodialysis indication and related activities including the upcoming read-out of Phase 3 results, the development of the product candidates in Humacyte's pipeline, and for working capital and general corporate purposes.

Subject to satisfaction of customary closing conditions, the offering is expected to close on or about 20 March 2026.

Titan Partners, a division of American Capital Partners, is acting as sole placement agent for the offering.